Literature DB >> 11506953

Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer.

S Loric1, V Paradis, J L Gala, P Berteau, P Bedossa, G Benoit, P Eschwège.   

Abstract

Until now, no molecular parameter has been available for predicting the metastatic potential of prostate tumours, which leaves their outcome uncertain despite an apparent benign histology or early stage. Abnormal expression of adhesion molecules, such as E-cadherin, can be contributing factors for increased invasiveness and metastatic potential. Histological analysis for E-cadherin expression was carried out on paraffin-embedded tumour tissues. Tumour metastatic potential was indirectly evaluated by detecting circulating prostate cells (CPC), using reverse transciptase-polymerase chain reaction (RT-PCR) and prostate-specific membrane antigen (PSMA) as a target. Patients were followed-up for a median of 14 months (range 10--19 months) after surgery with serum prostate-specific antigen (PSA) level measurement. Interestingly, 23 of 44 localised tumours exhibited aberrant E-cadherin expression. Prior to primary surgery, PSMA RT-PCR detected the spread of prostate cells to the blood in 24 patients. Statistical analysis showed that abnormal E-cadherin expression in the tumours was the only variable that was independently correlated with prostate cell dissemination in the blood (P<0.0001). In logistic regression analysis, abnormal E-cadherin expression was a significant independent predictor for a later biological relapse. This impaired adhesion status was clearly correlated with a haematogenous spread of the primary tumour cells. It could therefore be an objective way to restrict the indications for radical surgery to patients not presenting with this feature.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11506953     DOI: 10.1016/s0959-8049(01)00143-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  12 in total

1.  Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features.

Authors:  Catarina Ferreira; João Lobo; Luís Antunes; Paula Lopes; Carmen Jerónimo; Rui Henrique
Journal:  Virchows Arch       Date:  2018-07-13       Impact factor: 4.064

2.  ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading.

Authors:  Paul Mak; Irwin Leav; Bryan Pursell; Donggoo Bae; Xiaofang Yang; Cherie A Taglienti; Lindsey M Gouvin; Vishva M Sharma; Arthur M Mercurio
Journal:  Cancer Cell       Date:  2010-04-13       Impact factor: 31.743

3.  Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis.

Authors:  Daxing Xie; Crystal Gore; Jun Liu; Rey-Chen Pong; Ralph Mason; Guiyang Hao; Michael Long; Wareef Kabbani; Luyang Yu; Haifeng Zhang; Hong Chen; Xiankai Sun; David A Boothman; Wang Min; Jer-Tsong Hsieh
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-13       Impact factor: 11.205

4.  Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.

Authors:  Joseph Nariculam; Alex Freeman; Simon Bott; Phillipa Munson; Noriko Cable; Nicola Brookman-Amissah; Magali Williamson; Roger S Kirby; John Masters; Mark Feneley
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

5.  Cytokines and growth factors stimulate hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer.

Authors:  Geraldine Chow; Jordi Tauler; James L Mulshine
Journal:  J Biomed Biotechnol       Date:  2010-06-30

Review 6.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

7.  Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature.

Authors:  George J Klarmann; Elaine M Hurt; Lesley A Mathews; Xiaohu Zhang; Maria A Duhagon; Tashan Mistree; Suneetha B Thomas; William L Farrar
Journal:  Clin Exp Metastasis       Date:  2009-02-17       Impact factor: 5.150

8.  Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy.

Authors:  John C Cheville; R Jeffrey Karnes; Terry M Therneau; Farhad Kosari; Jan-Marie Munz; Lori Tillmans; Eati Basal; Laureano J Rangel; Eric Bergstralh; Irina V Kovtun; C D Savci-Heijink; Eric W Klee; George Vasmatzis
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

Review 9.  Biomarkers and mechanisms associated with recurrent prostate cancer.

Authors:  Sambad Sharma; Kounosuke Watabe
Journal:  Front Biosci (Landmark Ed)       Date:  2014-01-01

Review 10.  The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review.

Authors:  Naveen Kachroo; Vincent J Gnanapragasam
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-28       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.